Diagnosis of acute hepatitis C virus infection and estimated incidence in low- and high-risk English populations

Journal of Viral Hepatitis

Volumn 15, Issue 12, 2008, Pages 871-877

  Brant, L J ^a   Ramsay, M E ^a   Balogun, M A ^a   Boxall, E ^b   Hale, A ^c   Hurrelle, M ^c   Kaluba, L ^d   Klapper, P ^e   Lewis, D ^c   Patel, B C ^f   Parry, J ^a   Irving, W L ^d  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Acute infection; Hepatitis C virus; Incidence; Surveillance; Window period

Indexed keywords

INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; PRIORITY JOURNAL; VIRUS LOAD;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DRUG USERS; ENGLAND; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INCIDENCE; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL;

EID: 56549091687     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01009.x     Document Type: Article

References (27)

1. Manns MP., McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 (9286 958 965.
2. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 40 (6 993 999.
3. Hadziyannis SJ, Sette Jr H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 (5 346 355.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
5. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001 345 (20 1452 1457.
6. Kamal SM, Fouly AE, Kamel RR et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006 130 (3 632 638.
7. Kamal SM, Moustafa KN, Chen J et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006 43 (5 923 931.
8. Quiroga JA, Herrero M, Castillo I, Navas S, Pardo M, Carreno V. Long-term follow-up study of serum IgM antibody to hepatitis C virus (HCV), HCV replication, and liver disease outcome in chronic hepatitis C. J Infect Dis 1994 170 (3 669 673.
9. Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C. Hepatology 2002 1 : S195 S200.
10. Moller JM, Krarup HB. Diagnosis of acute hepatitis C: anti-HCV or HCV-RNA? Scand J Gastroenterol 2003 38 (5 556 558.
11. Aarons E, Grant P, Soldan K, Luton P, Tang J, Tedder R. Failure to diagnose recent hepatitis C virus infections in London injecting drug users. J Med Virol 2004 73 (4 548 553.
12. Judd A, Hickman M, Jones S et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2004 330 (7481 24 25.
13. Maher L, Jalaludin B, Chant KG et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006 101 (10 1499 1508.
14. Hagan H, Thiede H, Des J. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology 2004 15 (5 543 549.
15. Roy KM, Hutchinson SJ, Wadd S et al. Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect 2007 135 (3 433 442.
16. Champion JK, Taylor A, Hutchinson S et al. Incidence of hepatitis C virus infection and associated risk factors among Scottish prison inmates: a cohort study. Am J Epidemiol 2004 159 (5 514 519.
17. Page-Shafer K, Pappalardo BL, Tobler LH et al. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and project HCV incidence rates. J Clin Microbiol 2008 46 (2 499 506.
18. Brant LJ, Hurrelle M, Balogun MA et al. Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection. Epidemiol Infect 2007 135 (3 417 426.
19. Brant LJ, Hurrelle M, Balogun MA, Klapper P, Ramsay M, the hepatitis sentinel surveillance study group. Where are people being tested for anti-HCV in England? Results from sentinel laboratory surveillance. J Viral Hepat 2008 In press.
20. Health Protection Agency. Investigation of Hepatitis C infection. National Standard Method VSOP 5, London. Issue 5. 2005.
21. Harris KA, Gilham C, Mortimer PP, Teo CG. The most prevalent hepatitis C virus genotypes in England and Wales are 3a and 1a. J Med Virol 1999 58 (2 127 131.
22. Satten GA, Janssen R, Busch MP, Datta S. Validating marker-based incidence estimates in repeatedly screened populations. Biometrics 1999 55 (4 1224 1227.
23. Busch MP, Shafer KA. Acute-phase hepatitis C virus infection: implications for research, diagnosis, and treatment. Clin Infect Dis 2005 40 (7 959 961.
24. Busch MP. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients. Transfus Clin Biol 2001 8 (3 200 206.
25. Sypsa V, Touloumi G, Tassopoulos NC et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 2004 11 (4 366 374.
26. Department of Health. Good practice guidelines for Renal Dialysis/Transplantation Units. Prevention and Control of Blood-borne Virus Infection, 2002.
27. Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB. Shooting Up: Infections among injecting drug users in the United Kingdom 2006: an update, October 2007. London : HPA, 2007.